Found: 13
Select item for more details and to access through your institution.
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials.
- Published in:
- Breast Cancer Research & Treatment, 2020, v. 184, n. 1, p. 23, doi. 10.1007/s10549-020-05782-4
- By:
- Publication type:
- Article
Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer.
- Published in:
- PLoS ONE, 2020, v. 15, n. 4, p. 1, doi. 10.1371/journal.pone.0227256
- By:
- Publication type:
- Article
Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis.
- Published in:
- Clinical Chemistry, 2019, v. 65, n. 11, p. 1405, doi. 10.1373/clinchem.2019.305805
- By:
- Publication type:
- Article
Real‐World Data of Palbociclib in Combination With Endocrine Therapy for the Treatment of Metastatic Breast Cancer in Men.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 1, p. 302, doi. 10.1002/cpt.2454
- By:
- Publication type:
- Article
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer.
- Published in:
- Nature Communications, 2018, v. 9, p. 1, doi. 10.1038/s41467-018-03215-x
- By:
- Publication type:
- Article
Evaluation of the Association of Polymorphisms With Palbociclib‐Induced Neutropenia: Pharmacogenetic Analysis of PALOMA‐2/‐3.
- Published in:
- Oncologist, 2021, v. 26, n. 7, p. e1143, doi. 10.1002/onco.13811
- By:
- Publication type:
- Article
Hormone Receptor–Positive/Human Epidermal Growth Receptor 2–Negative Metastatic Breast Cancer in Young Women: Emerging Data in the Era of Molecularly Targeted Agents.
- Published in:
- Oncologist, 2020, v. 25, n. 6, p. e900, doi. 10.1634/theoncologist.2019-0729
- By:
- Publication type:
- Article
Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
- Published in:
- Oncologist, 2017, v. 22, n. 9, p. 1028, doi. 10.1634/theoncologist.2017-0072
- By:
- Publication type:
- Article
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).
- Published in:
- Oncologist, 2016, v. 21, n. 10, p. 1165, doi. 10.1634/theoncologist.2016-0097
- By:
- Publication type:
- Article
Crizotinib for the Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology.
- Published in:
- Oncologist, 2012, v. 17, n. 11, p. 1351, doi. 10.1634/theoncologist.2012-0311
- By:
- Publication type:
- Article
Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer.
- Published in:
- 2021
- By:
- Publication type:
- journal article